Back to top
more

KalVista Pharmaceuticals, Inc. (KALV)

(Delayed Data from NSDQ)

$15.12 USD

15.12
43,956

0.00 (0.00%)

Updated Feb 18, 2020 04:00 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.66%
17.94%
9.57%
5.30%
2.19%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

DVA RMD ENSG MEIP KALV

Zacks Equity Research

Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4

Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.

ZTS PCRX FGEN KALV

Zacks Equity Research

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

DVA RMD ENSG MEIP KALV

Zacks Equity Research

FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA

The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

AZN PCRX FGEN KALV

Zacks Equity Research

The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

CVGW KALV DAR CDNA SMPL

Zacks Equity Research

5 Defensive Stocks to Counter Coronavirus Scare

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

CVGW KALV DAR CDNA SMPL

Zacks Equity Research

BioLineRx Concludes Recruitment in Pancreatic Cancer Study

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

MRK RHHBY BLRX KALV

Zacks Equity Research

Will KalVista Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

KALV

Kinjel Shah

Prospects Appear Bright for Small Drug Industry in 2020

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.

MTNB KALV COLL AMRX

Zacks Equity Research

Will KalVista Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in KalVista.

KALV

Zacks Equity Research

KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

KALV

Zacks Equity Research

KalVista Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KALV

Zacks Equity Research

KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KALV

Zacks Equity Research

KalVista Group Sees Hammer Chart Pattern: Time to Buy?

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KALV

Zacks Equity Research

KalVista Pharmaceuticals Enters Oversold Territory

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KALV

Zacks Equity Research

Moving Average Crossover Alert: KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

KALV

Zacks Equity Research

Rigel Initiates Enrollment in Pivotal Blood Disorder Study

Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

AZN KALV RIGL ACRS

Zacks Equity Research

KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why

KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

KALV

Kinjel Shah

Small Drug Stocks Outlook: Near-Term Prospects Encouraging

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.

SLNO REPH RDUS ODT KALV HJLI

Kinjel Shah

Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

ATNM OTIC KALV ACRX MTEM ALPN TCDA

Zacks Equity Research

What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?

Does KalVista Pharmaceuticals (KALV) have what it takes to be a top stock pick for momentum investors? Let's find out.

KALV

Zacks Equity Research

Will KalVista Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

KALV

Zacks Equity Research

Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings

Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.

TCEHY ORCL KALV MRNS

Zacks Equity Research

Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?

Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.

TCEHY AVGO MRNS KALV

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 7th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th

OPHT LZB KALV GNCA